Zantac blow for Glaxo in US court ruling
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Glaxo Wellcome suffered a set-back last night when it was revealed that a US federal court gave the go-ahead for a rival company to start producing an unpatented form of Zantac, the anti-ulcer drug responsible for the British drug giant's success.
The District Court in Eastern North Carolina said plans by Novopharm USA, part of NovoPharm Biotech, to produce a generic form of the drug did not infringe a key patent held by Glaxo. The ruling will not open the floodgates to a wave of Zantac lookalikes, as the patent does not run out until July 1997, having been extended by the US authorities from December 1995. But it brings closer the prospect of widespread cheap competition after the middle of next year and is likely to hit Glaxo's shares when the market opens today.
In March, when Glaxo chief executive Sir Richard Sykes warned of the threat of increased generic competition, the share price fell sharply.
A Glaxo spokesman said last night: "We have indicated on a number of occasions that there was the potential for generic competition come July 1997 and this [ruling] does not change that ... While disappointed by the judge's decision, the company believes it has a valid case against NovoPharm and strong grounds for appeal to the US Court of Appeals for the Federal Circuit."
The news comes as Glaxo Wellcome's anti-Aids drugs are expected to be boosted by promising results of trials due to be released this week at a meeting of specialists in Canada.
Findings presented at the 11th international conference on Aids in Vancouver, which started over the weekend, should confirm the efficacy of Glaxo Wellcome's Retrovir and Epivir drugs. But most excitement will be reserved for news of three-way combinations with other pharmaceuticals and the latest clinical trials of a new compound code-named 1592, which has the potential to be better than either of the anti-Aids drugs.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments